Compare ARLO & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARLO | AGIO |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2018 | 2013 |
| Metric | ARLO | AGIO |
|---|---|---|
| Price | $11.37 | $27.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $24.00 | ★ $36.63 |
| AVG Volume (30 Days) | ★ 1.3M | 881.5K |
| Earning Date | 02-26-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $509,572,000.00 | $54,028,000.00 |
| Revenue This Year | $4.76 | $104.62 |
| Revenue Next Year | $7.37 | $125.15 |
| P/E Ratio | $281.43 | ★ N/A |
| Revenue Growth | N/A | ★ 48.03 |
| 52 Week Low | $7.84 | $22.24 |
| 52 Week High | $19.94 | $46.00 |
| Indicator | ARLO | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 31.89 | 51.41 |
| Support Level | $11.05 | $26.05 |
| Resistance Level | $12.82 | $29.93 |
| Average True Range (ATR) | 0.64 | 1.23 |
| MACD | -0.13 | 0.07 |
| Stochastic Oscillator | 15.55 | 49.36 |
Arlo Technologies Inc is engaged in the provision of security and video monitoring solutions for homes and businesses. It combines a cloud infrastructure and mobile app with various smart connected devices to provide users with visibility, insight, and a means to help protect and connect in real-time with the people and things from any location with a Wi-Fi or a cellular connection. The company offers subscription services such as Arlo Secure, Arlo Total Security, and Arlo Safe, and several categories of smart security devices, including smart Wi-Fi and LTE-enabled cameras, video doorbells, floodlight cameras, and home security systems. Geographically, the company generates a majority of its revenue from the United States, followed by Spain, Sweden, and other countries.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.